<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999476</url>
  </required_header>
  <id_info>
    <org_study_id>intubation in cancer tongue</org_study_id>
    <nct_id>NCT03999476</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Ambu® aScope2 for Intubation in Cancer Tongue</brief_title>
  <official_title>Randomized- Single Blind Trial of Ambu ascope2 and Fiberoptic in Severely Difficult Air Way Patient Having Posterior Third Fixed Tongue Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mahmoud salem soliman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the ascope2 with standard fiberscope using the nasal route of intubation
      in patient having sever difficult airway (having posterior one third cancer tongue with fixed
      mobility)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patient will be allocated into two group according to the type of endoscope used group (F)
      fibro scope group and group (A) the ambu ascope2 group The timer will be started (T0), when
      touching the fiberscope or a scope2. The standard fiberscope or a scope2 will be introduced
      through the nostril and advanced through the vocal cords, once carina identified the time
      will be recorded ( T1) When correct positioning of the trachea confirmed by detection of the
      end-tidal co2 curve on capnography (T2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel assignment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>patient will be under general anesthesia</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time of successful intubation</measure>
    <time_frame>5 minutes</time_frame>
    <description>measuring time in seconds for reaching carina and time for successful intubation
.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of vision</measure>
    <time_frame>5 minutes</time_frame>
    <description>subjective assessment by operator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of complications</measure>
    <time_frame>15 minutes</time_frame>
    <description>accounting number of desaturation , bleeding , hypoxia .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>easiness of intubation</measure>
    <time_frame>5 minutes</time_frame>
    <description>subjective assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of intubation trials</measure>
    <time_frame>30 minutes</time_frame>
    <description>counting number of intubation in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Difficult Intubation</condition>
  <arm_group>
    <arm_group_label>ambu scope2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intubation of cancer tongue patients with ambu scope2 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fiberoptic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intubation of cancer tongue patients with fiberoptic device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ambu ascope2</intervention_name>
    <description>nasal route intubation by the device in fixed cancer tongue patients</description>
    <arm_group_label>ambu scope2</arm_group_label>
    <other_name>Ambu® aScope™ 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fibreroptic bronchoscope</intervention_name>
    <description>nasal route intubation by the device in fixed cancer tongue patients</description>
    <arm_group_label>fiberoptic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients of ASA physical status I and II who will be scheduled for posterior
             third fixed cancer tongue with severe difficult airway requiring naso-tracheal
             intubation

          2. aged 18-70 years

        Exclusion Criteria:

          1. ASA 2 or 4

          2. pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekramy M Abdelghafar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alini Univeristy Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Giza</state>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Reeves DS, Brown NM. Mycobacterial contamination of fibreoptic bronchoscopes. J Hosp Infect. 1995 Jun;30 Suppl:531-6.</citation>
    <PMID>7560994</PMID>
  </reference>
  <reference>
    <citation>Han DW, Shim YH, Shin CS, Lee YW, Lee JS, Ahn SW. Estimation of the length of the nares-vocal cord. Anesth Analg. 2005 May;100(5):1533-5, table of contents.</citation>
    <PMID>15845720</PMID>
  </reference>
  <reference>
    <citation>Marfin AG, Iqbal R, Mihm F, Popat MT, Scott SH, Pandit JJ. Determination of the site of tracheal tube impingement during nasotracheal fibreoptic intubation. Anaesthesia. 2006 Jul;61(7):646-50.</citation>
    <PMID>16792609</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>mahmoud salem soliman</investigator_full_name>
    <investigator_title>Head of intensive care unit at new kaser al ainy teaching hospital , lecterur of anaesthesia and intensive care cairo universty .</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data for primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3 months</ipd_time_frame>
    <ipd_access_criteria>open</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

